Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q1 FY24 results · Apr–Jun 2023
Alivus Life Sciences reported revenue from operations of ₹578.45 crore (up 18.1% from Q1 FY23) and net profit of ₹135.45 crore (up 24.6% from Q1 FY23) for Q1 FY24 (Apr–Jun 2023), on a standalone basis.
| Item | Q1 FY24 | Q1 FY23 | YoY | Q4 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 578.45 | 489.87 | +18.1% | 621.32 | −6.9% |
| Other income | 1.85 | 9.49 | −80.5% | 2.84 | −34.7% |
| Total income | 580.30 | 499.36 | +16.2% | 624.16 | −7.0% |
| Profit before tax | 182.00 | 146.25 | +24.4% | 197.63 | −7.9% |
| Net profit for the period | 135.45 | 108.73 | +24.6% | 146.36 | −7.5% |
| EPS, basic (₹) | 11.05 | 8.87 | +24.6% | 11.94 | −7.5% |
| Net margin (%) | 23.4 | 22.2 | 23.6 |
Standalone
- Filed with BSE
- 21 Jul 2023, 16:41 IST
- Board meeting
- 21 Jul 2023
- Period
- 01 Apr 2023 to 30 Jun 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE